Actively Recruiting

Age: 18Years +
All Genders
NCT05967949

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2023-08-01

200

Participants Needed

1

Research Sites

261 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.

CONDITIONS

Official Title

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years and older
  • Male or female gender
  • Diagnosed with Peripheral T-cell Lymphoma (PTCL)
  • Received chidamide as maintenance therapy after first-line treatment
Not Eligible

You will not qualify if you...

  • Patients with other types of lymphomas
  • Pregnant women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hematological Department, People's Hospital of Jiangsu Province

Nanjing, Jiangsu, China, 210029

Actively Recruiting

Loading map...

Research Team

W

wei xu

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here